Jacobs Levy Equity Management
SGMO

Jacobs Levy Equity Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Jacobs Levy Equity Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,050,384
Closed -$506K – 1066
2026
Q1 		$506K Buy
2,050,384
+999,670
+95% +$398K ﹤0.01% 827
2025
Q4 		$441K Buy
1,050,714
+204,181
+24% +$108K ﹤0.01% 819
2025
Q3 		$570K Hold
846,533
– – ﹤0.01% 801
2025
Q2 		$458K Sell
846,533
-451,252
-35% -$268K ﹤0.01% 895
2025
Q1 		$851K Buy
1,297,785
+555,323
+75% +$588K ﹤0.01% 840
2024
Q4 		$757K Sell
742,462
-729,255
-50% -$1.33M ﹤0.01% 755
2024
Q3 		$1.27M Sell
1,471,717
-1,479,227
-50% -$1.08M ﹤0.01% 682
2024
Q2 		$1.06M Buy
2,950,944
+2,758,995
+1,437% +$1.49M ﹤0.01% 729
2024
Q1 		$129K Sell
191,949
-816,113
-81% -$592K ﹤0.01% 909
2023
Q4 		$548K Buy
1,008,062
+604,280
+150% +$279K ﹤0.01% 816
2023
Q3 		$242K Buy
403,782
+195,734
+94% +$210K ﹤0.01% 900
2023
Q2 		$270K Sell
208,048
-313,943
-60% -$429K ﹤0.01% 895
2023
Q1 		$919K Buy
521,991
+404,467
+344% +$1.15M 0.01% 716
2022
Q4 		$369K Sell
117,524
-12,265
-9% -$47.6K ﹤0.01% 836
2022
Q3 		$636K Buy
129,789
+30,779
+31% +$158K 0.01% 796
2022
Q2 		$410K Buy
+99,010
New +$428K ﹤0.01% 892
2018
Q1 		– Sell
-40,540
Closed -$665K – 1053
2017
Q4 		$665K Buy
40,540
+9,200
+29% +$137K 0.01% 699
2017
Q3 		$470K Buy
+31,340
New +$346K 0.01% 715

Other funds holding SGMO

NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
AIM
Axiom Investment Management New York $150M AUM
FTUS
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Jacobs Levy Equity Management's SGMO Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 2,050,384 shares — an estimated $506K sold.

Jacobs Levy Equity Management first reported a position in SGMO in Q3 2017 and held it in 18 quarters. The position peaked at $1.27M in Q3 2024. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 2,050,384 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $506K.
  • Jacobs Levy Equity Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 18 quarters.
  • Jacobs Levy Equity Management's SANGAMO THERAPEUTICS INC position peaked at $1.27M in Q3 2024.
  • 6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.